Refractory Malignant Neoplasm

14 clinical trials · Condition

Record	Firm	Date
Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer (NCT03203525)	M.D. Anderson Cancer Center	2020-06-23
Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy (NCT04409314)	University of California, San Francisco	2020-04-16
Financial Distress in Advanced Cancer Patients (NCT04053517)	M.D. Anderson Cancer Center	2019-07-02
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers (NCT03439085)	M.D. Anderson Cancer Center	2018-11-14
Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors (NCT03108131)	M.D. Anderson Cancer Center	2017-04-07
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer (NCT02595866)	National Cancer Institute (NCI)	2016-04-04
Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer (NCT02491632)	M.D. Anderson Cancer Center	2015-08-13
PCRC-Supported Legacy Intervention in Pediatric Palliative Care (NCT04059393)	Vanderbilt-Ingram Cancer Center	2015-07-27
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors (NCT02143401)	National Cancer Institute (NCI)	2015-01-30
Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes (NCT02286687)	M.D. Anderson Cancer Center	2014-12-22
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (NCT01552434)	M.D. Anderson Cancer Center	2012-10-16
Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers (NCT01624766)	M.D. Anderson Cancer Center	2012-06-19
Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer (NCT01582191)	M.D. Anderson Cancer Center	2012-05-14

Track Refractory Malignant Neoplasm automatically

Every clearance here is in the API, with alerts when new ones post.